Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments GlobeNewswire January 08, 2026 BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today […]